Summary
No substantiated on-label clinical claims were evaluated because the provided content appears to be a non-label coverage/cost/support discussion; the necessary FDA label alignment cannot be verified from the provided excerpts.
Category Scores
Accurate Statements
Cerdelga (eliglustat) is a branded prescription medicine.
Cerdelga is eligible for copay cards for commercially insured patients.
Cerdelga has patient assistance programs for eligible uninsured or underinsured patients.
Unsupported Statements
Cerdelga’s out-of-pocket cost can vary widely based on insurance coverage, pharmacy pricing, dosage, and whether the patient qualifies for manufacturer support.
No information about pricing, out-of-pocket cost drivers, or manufacturer support eligibility is present in the provided FDA label excerpts.
The main price drivers for Cerdelga are the manufacturer list price versus the negotiated cost the insurer pays, and the patient’s plan copay/coinsurance rules.
No information about list price/negotiated insurer cost or copay/coinsurance rules is present in the provided FDA label excerpts.
With insurance, the cost for Cerdelga is often a copay or coinsurance.
No information about insurance cost structure (copay/coinsurance) is present in the provided FDA label excerpts.
With insurance, the amount paid for Cerdelga depends on the formulary tier and whether prior authorization is required.
No information about formulary tier or prior authorization effects on patient payment is present in the provided FDA label excerpts.
Without insurance, the cost for Cerdelga is usually closer to the pharmacy cash price for the exact strength and quantity.
No information about uninsured cash pricing or the relationship between cash price and strength/quantity is present in the provided FDA label excerpts.
Cerdelga coverage support resources can be available for prior authorization or appeals.
No information about coverage support, prior authorization assistance, or appeals is present in the provided FDA label excerpts.
Copay cards and patient assistance programs for Cerdelga are eligibility-based and can change over time.
No information about copay card/program eligibility criteria or variability over time is present in the provided FDA label excerpts.
Contradictions
Important Omissions
No on-label prescribing information was provided to evaluate against FDA indications, dosage, contraindications, warnings/precautions, drug interactions, or adverse reactions for these claims.
Importance:
Moderate
Safety Assessment
Potential Patient Risk:
High
The claims focus on cost/access/support programs rather than label-based clinical use. Because the FDA label excerpts provided do not address these topics, there is a material risk of providing information that is not grounded in the official prescribing information.
Regulatory Assessment
| On Label |
No |
| Off-label Discussion |
No |
| Promotes Unapproved Use |
No |
| Hallucination Risk |
High |
Recommendation
Not Aligned
Primary Issue
Multiple statements are unsupported by the provided FDA prescribing information excerpts because they address pricing, copay/coinsurance, formulary/prior authorization, and patient support resources not covered in Sections 1, 2, 4, 5, 6, 7, and 8 excerpts.
Suggested Improvement
Limit statements to topics explicitly supported by the provided label excerpts (e.g., indications/limitations based on CYP2D6 metabolizer status, dosage selection/adjustment, contraindications/warnings about cardiac arrhythmias, and administration instructions). For cost or assistance-program details, use sources outside the prescribing information or clearly label them as non-FDA-label information.